(R)-2-羟基丁酸叔丁酯 | 206996-51-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (R)-2-羟基丁酸叔丁酯
• 中文别名: R-2-羟基丁酸叔丁酯
• 英文名称: (R)-2-hydroxy-butyric acid tert-butyl ester
• 英文别名: tert-Butyl (R)-2-hydroxybutyrate；tert-butyl (2R)-2-hydroxybutanoate
• CAS: 206996-51-2
• 化学式: C₈H₁₆O₃
• 分子量: 160.213
• InChiKey: UPRLOYNUXQZAPJ-ZCFIWIBFSA-N

物化性质

• 熔点：
  52-54 °C(lit.)
• 沸点：
  179.1±8.0 °C(Predicted)
• 密度：
  0.988±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S39
• 危险类别码：
  R41
• 海关编码：
  2918199090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319

制备方法与用途

用途 

手性结构单元

反应信息

• 作为反应物：
  描述：

  (R)-2-羟基丁酸叔丁酯 在 2,6-二甲基吡啶 、 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.42h， 生成 (2S)-2-{3'-[(5''-methylisoxazole-3''-carbonyl)amino]-2'-oxo-2'H-pyridin-1'-yl}butyric acid tert-butyl ester
  参考文献：
  名称：

  Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics

  摘要：

  The optimization of the pharmacokinetic performance of various 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors following oral administration to either beagle dogs or CM-monkeys is described. The molecules described in this work are composed of a 2-pyridone-containing peptidomimetic binding determinant and an alpha,beta-unsaturated ester Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. Modification of the ester contained within these compounds is detailed along with alteration of the P-2 substituent present in the peptidomimetic portion of the inhibitors. The pharmacokinetics of several inhibitors in both dogs and monkeys are described (7 h plasma concentrations after oral administration) along with their human plasma stabilities, stabilities in incubations with human, dog, and monkey microsomes and hepatocytes, Caco-2 permeabilities, and aqueous solubilities. Compounds containing an alpha,beta-unsaturated ethyl ester fragment and either an ethyl or propargyl. P-2 moiety displayed the most promising combination of 3C enzyme inhibition (k(obs)/[1] 170 000-223 000 M-1 s(-1)), antiviral activity (EC50 = 0.047-0.058 muM, mean vs seven HRV serotypes), and pharmacokinetics following oral administration (7 h dog plasma levels = 0.248-0.682 muM; 7 h CM-monkey plasma levels = 0.057-0.896 muM).

  DOI：

  10.1021/jm030166l
• 作为产物：
  描述：

  tert-butyl 2-oxobutyrate 在 9-[(1R,3R,4S,5R)-4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl]-9-borabicyclo[3.3.1]nonane 作用下， 反应 24.0h， 生成 (R)-2-羟基丁酸叔丁酯 、 (S)-2-羟基丁酸(-)-叔丁酯
  参考文献：
  名称：

  Selective reductions. 37. Asymmetric reduction of prochiral ketones with B-(3-pinanyl)-9-borabicyclo[3.3.1]nonane

  摘要：

  DOI：

  10.1021/jo00209a008

文献信息

• Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
  申请人：——

  公开号：US20010047006A1

  公开（公告）日：2001-11-29

  Compounds of the formula: 1 where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the picornaviral 3C protease. Also disclosed are compounds of the formula: 2 where the formula variables are as defined herein that advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as rhinovirus 3C proteases. Intermediates and synthetic methods for preparing such compounds are also described.

  披露了具有以下公式的化合物： 1 其中公式变量如本文所述定义，这些化合物能够有优势地抑制或阻断小RNA病毒3C蛋白酶的生物学活性。还披露了具有以下公式的化合物： 2 其中公式变量如本文所述定义，这些化合物能够有优势地抑制或阻断小RNA病毒3C蛋白酶的生物学活性。这些化合物以及含有这些化合物的药物组合物对于治疗感染了一种或多种小RNA病毒的患者或宿主是有用的，例如鼻病毒3C蛋白酶。还描述了用于制备这些化合物的中间体和合成方法。
• [EN] FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS<br/>[FR] DÉRIVÉS D'ACIDE GRAS POUR LE TRAITEMENT DE LA STÉATOHÉPATITE NON ALCOOLIQUE
  申请人：BASF AS

  公开号：WO2019111048A1

  公开（公告）日：2019-06-13

  The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

  本公开提供了一种用于治疗和/或预防非酒精性脂肪肝炎（NASH）和/或酒精性脂肪肝炎（ASH）的化合物。根据本发明使用的化合物是一种在β位含有氧原子的不饱和脂肪酸，并且还包含一个α-取代基。更具体地说，本发明提供了一种用于治疗NASH和/或ASH的化合物以及使用该方法，其中该化合物是公式（II），其中R1、R2、R3、X和Y如说明书中所定义；并且该化合物可以单独使用或与另一种活性剂结合使用。
• Caspase inhibitors and uses thereof
  申请人：——

  公开号：US20040242494A1

  公开（公告）日：2004-12-02

  The present invention provides a compound of formula I: 1 wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein. The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated diseases and processes for preparing the compounds of the invention.

  本发明提供了一种化合物，其化学式为： 1 其中R 1 ，R 2 ，R 3 ，R 4 和R 5 如本文所定义。本发明还提供了药物组合物和使用这种组合物治疗半胱天冬酶介导的疾病的方法，以及制备本发明化合物的方法。
• The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (<i>S</i>)-2-((2-(1-Isopropyl-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)
  作者：Timothy P. Heffron、Robert A. Heald、Chudi Ndubaku、BinQing Wei、Martin Augistin、Steven Do、Kyle Edgar、Charles Eigenbrot、Lori Friedman、Emanuela Gancia、Philip S. Jackson、Graham Jones、Aleksander Kolesnikov、Leslie B. Lee、John D. Lesnick、Cristina Lewis、Neville McLean、Mario Mörtl、Jim Nonomiya、Jodie Pang、Steve Price、Wei Wei Prior、Laurent Salphati、Steve Sideris、Steven T. Staben、Stefan Steinbacher、Vickie Tsui、Jeffrey Wallin、Deepak Sampath、Alan G. Olivero

  DOI：10.1021/acs.jmedchem.5b01483

  日期：2016.2.11

  Inhibitors of the class I phosphoinositide 3-kinase (PI3K) isoform PI3Kα have received substantial attention for their potential use in cancer therapy. Despite the particular attraction of targeting PI3Kα, achieving selectivity for the inhibition of this isoform has proved challenging. Herein we report the discovery of inhibitors of PI3Kα that have selectivity over the other class I isoforms and all

  I类磷酸肌醇3-激酶（PI3K）同工型PI3Kα的抑制剂因其在癌症治疗中的潜在用途而受到广泛关注。尽管靶向PI3Kα具有特别的吸引力，但事实证明，实现选择性抑制这种同工型具有挑战性。在此，我们报告发现了对其他I类同工型和所有其他测试激酶具有选择性的PI3Kα抑制剂。在GDC-0032（3（taselisib），我们之前相对于其他I类亚型降低了对PI3Kβ的抑制。随后，我们扩展了使用PI3Kα晶体结构鉴定PI3Kα特异性抑制剂的工作，从而通过与非保守残基的相互作用为对PI3Kα选择性具有选择性的苯并a庚因抑制剂的设计提供了信息。鉴定了相对于其他I类同工型和其他激酶对PI3Kα具有选择性的几种分子。优化与药物代谢相关的特性，最终确定了临床候选药物GDC-0326（4）。
• [EN] INDOLES HAVING ANTI-DIABETIC ACTIVITY<br/>[FR] INDOLES A ACTIVITE ANTIDIABETIQUE
  申请人：MERCK & CO INC

  公开号：WO2004020408A1

  公开（公告）日：2004-03-11

  Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

  印度戊酸取代的吲哚类化合物或芳基氧烷酸取代的吲哚类化合物是PPAR-γ的激动剂或部分激动剂，对于治疗和控制与2型糖尿病相关的症状性高血糖、以及常伴有2型糖尿病的血脂异常、高血脂、高胆固醇、高甘油三酯和肥胖等方面具有用处。